Drug details
Pifeltro (doravirine tablets)
type of HIV, NNRTIs
Pifeltro (doravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history.
The drug is often used to treat HIV .
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- diarrhea,
- fever,
- swollen glands,
- night sweats,
- weight loss,
- wheezing,
- weakness,
- cough,
- menstrual changes, and
- cold sores,
- trouble speaking or swallowing,
- problems with balance or eye movement,
- swelling in your neck or throat (enlarged thyroid),
- impotence
- prickly feeling,
The following drugs are related to Pifeltro, either as a replacement or used together:
- Ziagen (abacavir sulfate)
- Triumeq (abacavir, dolutegravir, and lamivudine film-coated tablets)
- Apretude (cabotegravir extended-release injectable suspension)
- Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide tablets)
- Cabenuva (cabotegravir; rilpivirine extended-release injectable suspension)
- Vocabria (cabotegravir tablets for oral use)
- Dovato (dolutegravir and lamivudine tablets)
- Juluca (dolutegravir and rilpivirine tablets, for oral use)
- Tivicay (doutegravir 50mg tablets)
- SYMFI (efavirenz, lamivudine and tenofovir disoproxil fumarate)
- Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate tablets)
- Emtriva (emtricitabine)
- Epivir (lamivudine)
- Epivir-HBV (lamivudine tablets and oral solution)
- Trogarzo (ibalizumab-uiyk injection)
- Selzentry (maraviroc)